<DOC>
	<DOC>NCT02908438</DOC>
	<brief_summary>The study was designed to investigate the effect of luteal-phase administration of gonadotrophin releasing hormone agonist(GnRHa) on pregnancy outcomes in in-vitro fertilization-embryo transfer.</brief_summary>
	<brief_title>Gonadotrophin Releasing Hormone Agonist Addition for Luteal Support in In-vitro Fertilization and Embryo Transfer Cycles</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<criteria>1. Age &lt; 37 years; 2. One or more high quality embryos have been got in IVF/ICSI treatment; 3. To transfer at lest 2 fresh embryos; 4. Uterine endometrial thickness ≥ 7mm; 5. Patients have signed informed consents. 1. ≥3 IVF/ICSI/FET cycles and no pregnancy; 2. Polycystic ovary syndrome(PCOS); 3. uterine malformation; 4. endometriosis 5. patients with a history of recurrent pregnancy loss.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>37 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>